Immunotherapy-based treatment strategies for malignant mesothelioma.
Malignant mesothelioma (MM) is a tumor of the pleura with an etiology that has been strongly linked to previous asbestos exposure. It is an almost universally fatal disease, regardless of tumor stage at the time of diagnosis. Current treatment modalities include surgery, chemotherapy and radiation therapy, although in some clinical trials none of these modalities have proven to be superior to no treatment at all. Knowledge of the tumor biology and immunology of this disease is insufficient, although several studies suggest feasibility and success for immunotherapeutic strategies. In this article, we review previous work and describe novel therapeutic approaches utilizing biological response modification for MM.
Louisiana State University Medical Center, Department of Medicine, Section Hematology/Oncology, 1542 Tulane Avenue, New Orleans, LA 70112, USA. pschwa1@isumc.edu
P
P
Schwarzenberger
P
P
Byrne
J K
JK
Kolls
D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D018122:B7-1 Antigen / Q000378:metabolism; D051940:B7-2 Antigen; D019496:Cancer Vaccines / Q000302:isolation & purification / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000378:metabolism; D015774:Ganciclovir / Q000627:therapeutic use; D015316:Genetic Therapy / Q000379:methods; D006649:Histocompatibility Antigens / Q000378:metabolism; D006801:Humans; D007111:Immunity, Cellular; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D008562:Membrane Glycoproteins / Q000378:metabolism; D008654:Mesothelioma / Q000276:immunology / Q000628:therapy*; D051379:Mice; D010997:Pleural Neoplasms / Q000276:immunology / Q000628:therapy*; D018139:Simplexvirus / Q000201:enzymology / Q000235:genetics; D013937:Thymidine Kinase / Q000235:genetics
D015703:Antigens, CD; D018122:B7-1 Antigen; D051940:B7-2 Antigen; C497964:CD86 protein, human; D019496:Cancer Vaccines; C497965:Cd86 protein, mouse; D016207:Cytokines; D006649:Histocompatibility Antigens; D007155:Immunologic Factors; D008562:Membrane Glycoproteins; D013937:Thymidine Kinase; D015774:Ganciclovir